CoChat
Sign Up
Cited by 51

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

LDL particle size: an important drug target?

Rajman, I., Eacho, Patrick I., Chowienczyk, P. J., Ritter, J. M.·1999·British Journal of Clinical Pharmacology
DOI 10.1046/j.1365-2125.1999.00991.x
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2125.1999.00991.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 80

  1. 10.1097/00041433-199410000-00002 · DOI
  2. Scandinavian Simvastatin Survival Study Group, 1995, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)., Lancet, 344, 1383
  3. 10.1056/NEJM199511163332001 · DOI · Paper page
  4. 10.1056/NEJM199610033351401 · DOI · Paper page
  5. 10.1016/S0002-9149(99)80474-3 · DOI
  6. 10.1172/JCI103182 · DOI
  7. 10.1161/01.ATV.7.5.483 · DOI
  8. 10.1073/pnas.72.6.2347 · DOI
  9. 10.1016/0026-0495(83)90194-4 · DOI
  10. Van Antwerpen R, 1994, Cryo‐electron microscopy reveals low density lipoprotein substructure., J Lipid Res, 35, 2223, 10.1016/S0022-2275(20)39928-4 · DOI
  11. 10.1097/00041433-199410000-00005 · DOI
  12. 10.1097/00041433-199412000-00002 · DOI
  13. Shen MMS, 1981, Heterogeneity of serum low density lipoproteins in normal human subjects., J Lipid Res, 22, 236, 10.1016/S0022-2275(20)35367-0 · DOI
  14. 10.1016/0167-4838(90)90100-T · DOI
  15. Musliner TA, 1988, Lipoprotein subspecies and risk of coronary disease., Clin Chem, 34, B78
  16. 10.1001/jama.260.13.1917 · DOI
  17. 10.1161/01.ATV.13.5.702 · DOI
  18. 10.1016/0005-2760(93)90294-J · DOI
  19. La Belle M, 1990, Differences in carbohydrate content of LDL lipoproteins associated with LDL subclass patterns., J Lipid Res, 31, 1577, 10.1016/S0022-2275(20)42342-9 · DOI
  20. 10.1097/00019501-199304000-00010 · DOI
  21. 10.1016/0005-2760(95)00172-7 · DOI
  22. 10.1093/oxfordjournals.qjmed.a068888 · DOI
  23. 10.1161/01.ATV.12.11.1284 · DOI
  24. 10.1097/00041433-199405030-00007 · DOI
  25. 10.1073/pnas.89.2.708 · DOI
  26. HamstenA KarpeFTriglycerides and coronary heart disease—has epidemiology given us the right answer? InLipids: Current Perspective Vol. 1 ed. Betteridge DJ 199643–63
  27. 10.1097/00041433-199412000-00002 · DOI
  28. 10.1016/0021-9150(94)90129-5 · DOI · Paper page
  29. 10.1016/0021-9150(96)05881-9 · DOI
  30. 10.1161/01.CIR.95.1.69 · DOI · Paper page
  31. 10.1172/JCI116541 · DOI
  32. 10.1016/0026-0495(95)90134-5 · DOI
  33. 10.1161/01.RES.77.3.510 · DOI
  34. 10.1038/327237a0 · DOI
  35. 10.1161/01.ATV.14.5.653 · DOI
  36. 10.1038/320454a0 · DOI
  37. 10.1097/00041433-199408000-00002 · DOI
  38. 10.1056/NEJM198904063201407 · DOI
  39. 10.1161/01.ATV.11.2.298 · DOI
  40. 10.1016/0006-2952(95)02072-1 · DOI
  41. 10.1097/00041433-199508000-00003 · DOI
  42. Nigon E, 1991, Discrete subspecies of human LDL are heterogeneous in their interactions with the cellular LDL receptor., J Lipid Res, 32, 1741, 10.1016/S0022-2275(20)41629-3 · DOI
  43. Galeano NF, 1994, Apoprotein B structure and receptor recognition of triglyceride rich low density lipoprotein is modified in small LDL but not in triglyceride rich LDL of normal size., J Biol Chem, 269, 511, 10.1016/S0021-9258(17)42379-9 · DOI
  44. Chen GC, 1994, Conformational differences in human apolipoprotein B‐100 among subspecies of LDL. Association of altered proteolytic accessibility with decreased receptor binding of LDL subspecies from subjects., J Biol Chem, 269, 29 121, 10.1016/S0021-9258(19)62020-X · DOI
  45. 10.1161/01.ATV.17.11.2507 · DOI
  46. Galeano NF, 1998, Small dense low density lipoprotein has increased affinity for LDL receptor‐independent cell surface binding sites: a potential mechanism for increased atherogenicity,, J Lipid Res, 39, 1263, 10.1016/S0022-2275(20)32551-7 · DOI
  47. Dyce MC, 1993, Indices of LDL particle size closely relate to endothelial dysfunction., Circulation, 88, I 466
  48. 10.1006/bbrc.1993.1550 · DOI
  49. 10.1016/0021-9150(90)90131-2 · DOI
  50. Krauss RM, 1982, Identification of multiple subclasses of plasma low density lipoproteins in normal humans., J Lipid Res, 23, 97, 10.1016/S0022-2275(20)38178-5 · DOI
  51. Naito HK, 1973, Polyacrylamide gel disc electrophoresis as a screening procedure for serum lipoprotein abnormalities., Clin Chem, 19, 228, 10.1093/clinchem/19.2.228 · DOI
  52. Muniz N, 1977, Measurement of plasma lipoproteins by electrophoresis on polyacrylamide gel., Clin Chem, 10, 1826, 10.1093/clinchem/23.10.1826 · DOI
  53. Naito H, 1995, LDL particle size decreases in non‐insulin dependant diabetic patients with nephropathy., J Japan Diab Soc, 38, 615
  54. 10.1016/S0002-9149(99)80552-9 · DOI
  55. 10.1007/BF00192552 · DOI
  56. 10.1161/01.ATV.14.10.1569 · DOI
  57. 10.1111/j.1365-2796.1991.tb00370.x · DOI
  58. Bakker‐Arkema RG, 1996, Efficacy and safety of a new HMG CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia., JAMA, 275, 128, 10.1001/jama.1996.03530260042029 · DOI
  59. 10.1016/S0021-9150(97)88234-2 · DOI
  60. 10.1111/j.1365-2362.1992.tb01478.x · DOI
  61. 10.1016/S0002-9149(98)00039-3 · DOI
  62. 10.1016/0021-9150(92)90177-I · DOI
  63. 10.1016/0021-9150(92)90173-E · DOI
  64. 10.1016/0021-9150(93)90071-2 · DOI
  65. 10.1016/0021-9150(94)90062-0 · DOI
  66. 10.1016/0021-9150(92)90173-E · DOI
  67. 10.1161/01.ATV.16.6.763 · DOI
  68. 10.1016/S0140-6736(96)91343-4 · DOI
  69. 10.3109/07853899109148041 · DOI
  70. 10.1056/NEJM199610313351804 · DOI · Paper page
  71. 10.1056/NEJM199411033311803 · DOI
  72. 10.1016/S0140-6736(98)22003-4 · DOI
  73. 10.2337/diacare.21.5.796 · DOI
  74. 10.1007/s001250050658 · DOI
  75. 10.1016/0021-9150(96)05811-X · DOI
  76. Ghazzi MN, 1997, Cardiac and glycemic benefits of troglitazone treatment in NIDDM., Diabetes, 46, 433, 10.2337/diab.46.3.433 · DOI
  77. Lehmann JM, 1995, An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator receptor g (PPARg)., J Biol Chem, 270, 12 953, 10.1074/jbc.270.22.12953 · DOI
  78. 10.1016/S0021-9150(97)00315-8 · DOI
  79. Schoonjans K, 1996, Role of peroxisome proliferator‐activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression., J Lipid Res, 37, 907, 10.1016/S0022-2275(20)42003-6 · DOI · Paper page
  80. 10.2337/diabetes.47.12.1841 · DOI

Cited by

Sorted by citations

Metadata

Authors
Rajman, I., Eacho, P. I., Chowienczyk, P. J., & Ritter, J. M.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
1999-08
Volume
48
Issue
2
Pages
125-133
ISSN
  • 0306-5251
  • 1365-2125
DOI
10.1046/j.1365-2125.1999.00991.x
Cited by
51
References
3
Language
en
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor, 876 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review